Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who fully understand the study and are willing to sign a consent form agreeing to take part.
• Adults aged 18 or older at the time of signing the consent form.
• People who have been diagnosed with a specific type of pancreatic cancer (pancreatic ductal adenocarcinoma, including adenosquamous carcinoma) confirmed by a tissue or cell sample.
• People who have not yet received any systemic (whole-body) treatment for pancreatic cancer that cannot be surgically removed, has spread locally, or has spread to other parts of the body.
• People who have at least one tumour that can be measured on a scan, according to standard medical criteria.
• People whose general physical health and ability to carry out daily activities is rated as good or fully active (rated 0 or 1 on a standard medical scale).
• People whose doctor estimates they have a life expectancy of at least 3 months.
• People who have recovered from side effects of any previous cancer treatments to a mild or stable level, as assessed by the treating doctor (some exceptions apply, such as ongoing hair loss or mild nerve-related symptoms).
• People whose blood counts, liver, kidney, and clotting functions meet the required levels as assessed by the trial site.
• Women who are not pregnant and not breastfeeding, and who either cannot become pregnant or agree to use contraception as directed by the trial.

Who may not be able to join:

• People who have had major surgery or a serious physical injury within 28 days before starting the trial treatment.
• People who are known to carry BRCA1 or BRCA2 gene mutations.
• People who have received systemic cancer treatment — including chemotherapy, targeted therapy, immunotherapy, or experimental drugs — within 28 days before starting the trial treatment.
• People who have previously received certain types of immunotherapy that target specific immune checkpoints (such as PD-1, PD-L1, or CTLA-4 blockers), or who have previously been treated with a type of drug called a FAK inhibitor.
• People who have received high-dose (radical) radiotherapy within 3 months before starting the trial, or lower-dose (palliative) radiotherapy to a specific area within 2 weeks before starting the trial.
• People who have previously had a bone marrow stem cell transplant or an organ transplant.
• People who have received a live or live-attenuated vaccine within 28 days before starting the trial treatment.
• People who have interstitial lung disease or other significant lung conditions.
• People who have a history of, or currently have, an active autoimmune disease.
• People who have had another cancer diagnosed within the past 5 years, except for certain treated skin cancers, non-invasive bladder cancer, or some cancers detected at a very early stage (confirm with trial site).
• People who have active cancer that has spread to the brain or the lining surrounding the brain or spinal cord.
• People who have had a serious heart, stroke, or blood clot event within the 6 months before starting the trial.
• People with an active infection that is not well controlled with treatment.
• People with HIV infection, active hepatitis B or C, or active syphilis or tuberculosis.
• People with any other medical condition, treatment history, or test result that the treating doctor believes could affect the trial results or may not be in the person's best interest.

Important: Always verify eligibility with the trial site directly before applying.